5O'Brien SG,Guilhot F,Larson RA,et al.Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.N Engl J Med,(2003a),348:994.
6Hans-Peter Gschwind,Ulrike Pfaar,Felix Waldmeier,et al.Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos ,2005,33(10):1503.
8Kwon H,Lionberger RA,LX Yu.Impact of P-glycoprotein-mediated intestinal Efflux Kinetics on oral bioavailability of P-glycoprotein substrates.Molecul Pharm, 2004,6(1):455.
9Chowdhury MM,Kim DH,Ahn JK.A physiologically based pharmacokinetic model for absorption and distribution of imatinib in human body.Bull Korean Chem Soc,2011,32(11):3967.
10Szczepek WJ,Kosmacinska B,Bielejewska A,et al.Identification of imatinib mesylate degradation products obtained under stress conditions. J Pharm Biomed Anal, 2007,43:1682.
